Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Blood Advances|August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapyVincent Camus, Roch Houot, Gabriel Brisou, et al.Blood Advances|February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jérôme Lambert, et al.American Journal of Hematology|August 4, 2020
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European centerPierre Sesques, Emmanuelle Ferrant, Violaine Safar, et al.Blood Advances|October 22, 2025
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registryFederico Erbella, Emmannuel Bachy, Guillaume Cartron, et al.Cell Metabolism|March 5, 2019
GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic InhibitorsJohanna Chiche, Julie Reverso-Meinietti, Annabelle Mouchotte, et al.Hemasphere|May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA groupPierre Sesques, Guillaume Manson, Guillaume Cartron, et al.Journal of Hematology & Oncology|August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphomaPierre Sesques, Amy A Kirkwood, Mi Kwon, et al.European Journal of Cancer (Oxford, England : 1990)|December 6, 2025
Large B-cell lymphoma: The LYSA pragmatic guidelinesPierre Sesques, Guillaume Manson, Sydney Dubois, et al.Pageof 3